Alzheimer's disease (AD) is the most prevalent neurodegenerative disease in ageing,
affecting around 46 million people worldwide but few treatments are currently available. The …

Globally, there is a huge unmet need for effective treatments for neurodegenerative
diseases. The complexity of the molecular mechanisms underlying neuronal degeneration …

In this paper, we explore the utility of resting-state EEG measures as potential biomarkers for
the detection and assessment of cognitive decline in mild cognitive impairment (MCI) and …

Animal models are indispensable tools for Alzheimer disease (AD) research. Over the
course of more than two decades, an increasing number of complementary rodent models …

Frontotemporal lobar degeneration (FTLD) is one of the most common causes of early-onset
dementia and presents with early social–emotional–behavioural and/or language changes …

Pathological perturbations of the brain are rarely confined to a single locus; instead, they
often spread via axonal pathways to influence other regions. Patterns of such disease …

LncRNAs have attracted lots of attentions from researchers worldwide in recent decades.
With the rapid advances in both experimental technology and computational prediction …

Highlights•Recent GWAS identified microglia-related pathways as risk factors for
Alzheimer's.•Role of immune molecules in synapse loss, a hallmark of Alzheimer's, is poorly …

In Alzheimer's disease (AD), memory impairment is the most prominent feature that afflicts
patients and their families. Although reactive astrocytes have been observed around …

In Alzheimer's disease (AD), β-amyloid (Aβ) plaques are tightly enveloped by microglia
processes, but the significance of this phenomenon is unknown. Here we show that …